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Objective: To investigate and compare the incidence and type of complications related to central venous catheters in 
AIDS patients and in two control groups of non-AIDS patients. 
Methods: Three groups of patients requiring permanent venous access were investigated retrospectively between 
January 1988 and January 1994. The indication for Port-A-Cath system implantation in AIDS patients was administration 
of virustatics and/or total parenteral nutrition (TPN) (group A, n=71), in non-AIDS immunocompromised patients it was 
chemotherapy (group B, n=65) and in immunocompetent patients it was home TPN (group C, n=14). Complications 
were categorized into infectious complications and non-infectious complications, and related to  patient characteristics, 
degree of immunosuppression, type of therapeutic medium, insertion technique and catheter survival time. 
Results: Type of complications could not be related to type of insertion procedure or length of operation. Catheter- 
related mortality was low in  all groups (0-1%). Type of complications could be related to catheter survival time in all 
groups. Infectious complications could not be related to degree of immunosuppression (CD4+ lymphocyte counts or 
white blood cell count). Unexpectedly, the incidence of both infectious and non-infectious complications was 
significantly higher for group C than for groups A and B, probably because of type of medium and/or differences in 
handling of the catheter. 
Conclusion: In this retrospective study, central venous catheters appear to be safe and are well tolerated by AIDS 
patients, as compared to non-AIDS immunocompromised patients receiving chemotherapy and immunocompetent 
home-TPN patients. 
Key words: Central venous catheters, AIDS, non-infectious complications, infectious complications, irnmuno- 
compromised, immunocompetent 
INTRODUCTION 
Pcrmment  acc.e5s to the bloodstreani for clinicd 
nimagement IS frequently nceded in patients with 
AIIX.  I n  1984, t o td l y  iiiiplantable venous access 
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devices, such as I'or t- A-C '1 t h  (PAC), became available. 
Advaritagcs of these central venous c'itheter7 over 
the coriservative systems such :is the subcutaneourly 
tunneled right atrial catheters (Broviac 'ind Hickman 
I1,2]) are t h a t  they arc lecs liable t o  infection and  
esthetically more cicceptcible. Therefore, these totally 
implantable central venous catheters are now comnionly 
used for repeated or pernimcnt clinic'il niaiiCigetiient 
~ n d  home care of  p,itients with AIIIS. Several author5 
have exanlined the c o  m pli cati ons of central venous 
catheters in AIDS patients o r  non-AIDS patient\ 
13-1 81. They reported vari'ible complication rates, duc 
t o  differcncez i n  the type of catheter used. p'itient 
population 'ind definition$ of complicxions 13-1 81. I n  
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AIDS patients, infectious complications, such as in- 
fection at the incision site, tunnel infection, septic 
phlebitis or septicemia, have been particularly reported 
[3-61. Only one study describes non-infectious 
complications in AIDS patients. These complications 
consisted of catheter occlusion, catheter-related bleed- 
ing and venous clotting [4]. To our knowledge, no 
study has been reported in which both infectious and 
non-infectious complications are determined in AIDS 
patients and compared to a control group of patients. 
Therefore, the present study was designed to 
investigate retrospectively and compare type and 
incidence of complications related to totally implanted 
central venous catheters in three groups of patients: 
AIDS patients, non-AIDS immunocompromised 
patients receiving chemotherapy and immunocom- 
petent patients receiving home total parenteral nutrition 
(TPN). Complications were categorized into infectious 
complications and non-infectious complications, and 
related to patient characteristics, degree of immuno- 
suppression, insertion technique, type of fluids and 
agents administered through the catheter and catheter 
survival time. 
PATIENTS AND METHODS 
Patients 
The medical records of the patients in the Academic 
Medical Center (Amsterdam, The Netherlands) who 
received at least one Port-A-Cath (PAC) (SIMS Co., 
Minneapolis, USA) during the period from January 
1988 to January 1994 were analyzed retrospectively. 
Three patient groups were examined. Group A 
consisted of patients with the diagnosis of AIDS 
according to the revised 1987 Centers for Disease 
Control case definition [19]. Two groups were used as 
control groups: immunocompromised patients with a 
diagnosis of solid tumor, lymphoma, or acute or 
chronic leukemia and treated with chemotherapeutic 
agents (group B); and patients without immuno- 
suppression with a diagnosis of short bowel syndrome, 
pseudo-obstruction syndrome or Crohn’s disease and 
treated with home TPN (group C). 
The administration of fluids and/or agents was 
different in the three groups. In group A agents were 
given by a doctor/nurse or the patients’ relatives; 
patients from group B were always treated by a 
doctor/nurse; and group C administered agents them- 
selves. With respect to the period of PAC use, group 
A had a PAC until death or the occurrence of a 
complication that could not be resolved by conservative 
measures. Group B also kept their PAC until com- 
plication or death, but in this group the PAC was also 
removed at the end of chemotherapeutic treatment. 
The use of the PAC in group C was comparable to that 
in group B, except that in general the required period 
of PAC use was much longer. 
Type of catheter 
Venous access systems in the different groups ofpatients 
mainly consisted of PACs. The analysis was limited to 
those complications that occurred with PAC. Only for 
the analysis of the possible relation of these PAC 
complications to previous catheter implantations were 
the subcutaneously tunneled catheters (Broviac or 
Hickman type) also taken into account. 
Catheter placement 
The surgical procedure for totally implanted catheters 
was performed in one of two ways. Under local or 
general anesthesia, the catheter was introduced either 
percutaneously (venipuncture technique) or after 
phlebotomy (venisection technique) into the superior 
vena cava via either the internal jugular vein, the 
external jugular vein or the subclavian vein with the aid 
of a peel-off sheath. The catheter tip was placed in the 
superior vena cava at the entry of the right atrium. 
Catheter tip location and the absence of pneumo-thorax 
were checked by chest radiography before admini- 
stration of drugs, intravenous fluids or TPN solutions. 
Data collection 
Data collected included patients’ characteristics such as 
age and sex, immune status (CD4+ lymphocyte counts 
or total white blood cell (WBC) counts) and catheter 
survival time. CD4’ lymphocyte counts and WBC 
counts, assessed within a maximum of 6 weeks before 
PAC iniplantation, were considered to be representative 
for the patients’ immune status during implantation. 
However, it should be realized that immunosuppression 
in patients of group B is mostly encountered after 
initiation of chemotherapy. Date of catheter insertion 
and removal, indication and number of previous 
catheter placements (includmg previous subcutaneously 
tunneled catheters), duration of catheterization pro- 
cedure, insertion technique, type of fluids and agents 
administered through catheter (chemotherapeutics, 
antibiotics, virustatics, parenteral nutrition, blood 
products, intravenous fluids, corticosteroids), cultures 
of catheter tip if indicated and position of the tip were 
scored. Two types of catheter-related complications 
were identified: infectious and non-infectious com- 
plications. There was special attention to specific 
treatment of complications. 
Definitions 
The diagnosis of infectious complications was based 
upon documentation of the following. 
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Incision site infiction: presence of erythema, tender- 
ness, induration, or purulence due to an abscess, or 
any combination of these, near the incision site. 
Catheter-related septic phlebitis: development of oc- 
clusion of the vein in which the catheter is placed, 
in proximity to a local site of infection, associated 
with bacteremia and fever. 
Catheter-related bacterernia: development of fever and 
bacteremia due to infected central venous catheter, 
a? shown by positive catheter tip culture. 
Bacterernia .f unknown origin, probably catheter-related: 
development of fever and bacteremia in a patient 
with asymptomatic central venous catheter-system, 
with no known focus of infection, resolving upon 
removal of the catheter within 36 h. 
The following definitions were used for the diagnosis 
of non-infectious complications: 
B l e e d i y :  significant blood loss related to catheter 
placement with a decline of hemoglobin concen- 
tration of at  least 1 .O nimol/L. 
Subcutaneous Izernatoma: a subcutaneously localized 
mass of extravasated blood related to catheter place- 
ment. 
Catheter occlusion: inability to infuse fluids and/or 
aspirate blood despite previous installation of strepto- 
kinase. 
Inmrrert position .f catheter: any other location of the 
catheter tip than in the superior vena cava at  the 
entry of the right atrium. 
Reservoir leakage: damage of system connections or 
extravasation of solution due to incorrect injection 
(outside the system) and necessitating removal of the 
catheter. 
Statistical analysis 
To compare complication incidences between the three 
groups, a competing risk analysis was used, where both 
complications and death of the patient were considered 
to be competing risks. As the first 12 months were 
considered to be relevant for the survival of an AIDS 
patient, once in need of a PAC, only 12 months of 
follow-up were taken into account in the analysis of the 
three groups. To test for differences between groups 
with respect to cumulative incidences a Gray test was 
used. To test for differences between proportions, the 
chi-squared test was used. The relation between the 
preoperative CD4+ lymphocyte count or WBC count 
and the development of infectious complications was 
analyzed using the Cox regression model. A p-value less 
than 0.05 was considered to be significant. 
RESULTS 
One hundred and fifty patients (group A, 71 ; group B, 
65; group C, 14) were available for analysis during the 
study period. All 71 patients of group A had a diagnosis 
of AIDS. Fifcy-three patients of group I3 had a diagnosis 
of a solid tunior, eight had leukemia, and four had 
lymphomas. In group C, 10 patients had short bowel 
syndrome, three patients had pseudo-obstruction 
syndrome and one patient suffered from Crohn's disease 
with Fevere nialabsorption. Patient characteristics and 
immune status are shown in Table 1. 
Indications for catheter placement 
One hundred and eighty-nine devices were implanted. 
Catheter-related data are shown in Table 2. The need 
for intravenous administration of non-chernothera- 
peutic drugs (ganciclovir, foscarnet, ainphotericin B) 
was the indication for device implantation in 66 (93%)) 
patients of group A and in no patients of either group 
B or C. The need for chemotherapy was the indication 
for device implantation in no patients of group A, in 
65 (100%) patients of group B, and in no patients of 
group C. TPN was given to five (7%) patients of group 
Table 1 Patient characteristics and immune status of patients in groups A, €3 and C 
Group A (koup B Group C 
Nuinber of paticnts 71 65 14 
Male/fernaie 70/ 1 33/32 618 
Mean age (range) iii year5 -10.1 (2.5-57) 52.9 (18-77) 47.2 (25-66) 
Mean CDI' lyniphocyte counts 5 0  (10-780)d Not doiic Nor done 
Mean WBC counts 1.2 (0.3-1.2)' 2.4 (0.9-43)' 9.6 (5.7-21 4)'  
(X 106/L) (range) 
(X 10y/L)" (range) 
"Within h weekv prior to surgery 
"y<O.OS (betwt.cn groups). 
'Deepevt dip of WBC during chemotherapy. 
Group A consisted of AIDS patients; group B consisted of immunoco~npromised patient5 with 3 diagnow of uohd tumor, lymphoma. or 
~ c t i t e  or chronic leukrinia, and treated with chemotherapeutic agents; group C consistrd of paticnts with negligible immuIiosuppres5ioii 
with a diagnovis of short bowel syndrome, pseudo-obstruction Fyndrome or Crohni  disease. 
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Table 2 Catheter related data for patients in groups A, B, and C 
Group A 
~ 
Group B Group C 
~ 
Catheter-type: Port-a-Cath 
Number of introductions with puncture 
Number of introductions with venisections 
Number of reinsertions 
Mean operation time 
Mean catheter survival 
Complications per 100 catheter days 



































~ ~ ~ ~ ~~~~~~~~~~ 
'Including induction and end of anesthesia and delivery of chest X-ray 
Group A consisted of AIDS patients, group B consisted of immunocompromsed patients with a dagnosis of solid tumor, lymphoma, or 
acute or chronic leukerma, and treated with chemotherapeunc agents, group C consisted of patients with negligible immunosuppression 
with a diagnosis of short bowel syndrome, pseudo-obstruction syndrome or Crohn's disease 
Table 3 Type and number of infectious and non-infectious complications in groups A, B and C 
Group A (n=71) Group B (n=65) Group C (n=14) 
Number of infectious complications ('Yo) 
Incision site infection 
Catheter-related septic phlebitis 
Catheter-related bacteremia 
Probably catheter-related bactererma 





































"One patient had a pneumothorax and one patient developed pulmonary embolism. 
Group A consisted of AIDS patients; group B consisted of immunocompromised patients with a diagnosis of solid tumor, lymphoma, or 
acute or chronic leukemia, and treated with chemotherapeutic agents; group C consisted of patients with negligible immunosuppression 
with a diagnosis of short bowel syndrome, pseudo-obstruction syndrome or Crohn's disease. 
A, to six (9%) patients of group B, and to 14 (100%) 
patients of group C. Other media used included blood 
products, antibiotics, corticosteroids and intravenous 
fluids. 
Complications 
The type and incidence of infectious complications and 
non-infectious complications are shown in Table 3. 
Successful conservative measures after complications 
were taken in 66% (21/32 complications), 50% (12/24 
complications), and 38% (1 1/29 complications) in 
groups A, B and C, respectively. Conservative measures 
consisted of antibiotic treatment, or flushing of catheter 
with NaCl 0.9% or alkaline solutions. Removal of 
devices was performed in 44% (1 4/32 complications), 
46% (11/24 complications) and 66% (19/29 com- 
plications) after complications in groups A, B and C, 
respectively. 
Catheter-related mortality was low in all groups: 
1.4% (1/71 patients), 0% and 0% for groups A, B 
and C. respectively. One patient in group A died of 
catheter-related bacteremia. 
Type of complication could not be related to type 
of insertion procedure or length of operation (data not 
shown). The cumulative incidence of complications 
per month for each group is shown in Figure 1. 
Statistical comparison for each group showed that the 
cumulative incidence of complications was significantly 
higher in group C than in the other groups (p<0.05). 
Infectious complications 
Twelve (17%) patients of group A had 19 infectious 
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2 4 6 8 10 12 0.0 
follow-up in months 
-- groupA 71 58 40 26 20 12 8 - group6 65 47 34 28 21 16 14 
groupC 14 13 12 12 12 12 12 
Figure 1 Cumulative incidence of complications per 
m o n t h  for the three different groups. Group A (interrupted 
line) consiyted of AIDS patients; group B (thick line) 
consisted of ininiunocomproniised patients with a diagnosis 
of solid tunior, lymphoma, or acute or chronic leukemia, 
and treated with chemotherapeutic agents; group C (thin 
line) consisted of patients with negligible immuno- 
suppression with a diagnosis of short bowel syndrome, 
pseudo-obstruction yyndronic or Crohn's disease. 
complications, eight (12%) patients of group B had 
eight infectious complications, and eight (57%) patients 
of group C had eight infectious complications. The 
cumulative incidence of infection per month was 
significantly greater in group C than in the other two 
groups (p<O.O5). In all groups, previous catheter 
infection and length of present catheter stay could be 
associated with increased risk of infection (data not 
shown). 
A causative microorganism could be isolated for 22 
of the 35 infectious complications: Staplzylocorctrs aiireiis 
(1 0/22)  or Staphylococc~s epidertnidis (12/22). There was 
no statistically significant relation between immune 
status (CD4+ lymphocyte counts) and occurrence of 
infectious complications within patients of group A. 
The mean WBC count was highest (9.6x109/L) in 
patients ofgroup C and lowest (1.2 x109/L) in patients 
of group A (Table 1). Low WBC counts did not have 
a predictive value for the development of infectious 
complications between and within the three groups 
Non-infectious comp/ications 
Nine (1 3%) patients of group A had 13 non-infectious 
complications, 13 (20%) patients of group B had 16 
non-infectious complications, and 14 (100%) patients 
of group C had 21 non-infectious complications 
(Table 3). The cumulative incidence of non-infectious 
complications per month was significantly higher in 
group C than in groups A and B (p<0.05). In all 
groups, catheter survival time could be associated with 
increased risk of catheter occlusion. The longer the 
catheter was used, the higher the risk of catheter 
occlusion. In groups A and B, catheter occlusions were 
caused by TPN or blood products, and in group C 
catheter occlusions were exclusively caused by TPN. 
TPN use could be related to occurrence of catheter 
occlusions in all groups and within each group 
Bleeding in one patient of group C was due to 
thrombocytopenia. Reservoir leakage was due to 
malinjection by the doctor/nurse (group B) or the 
patients themselves (group C ) ;  it did not occur in group 
A. 
( p  < 0.05). 
DISCUSSION 
Totally implantable central venous catheters are 
frequently used in AIDS patients, making life-long 
intravenous therapy possible in the home-care setting. 
Theoretically, many complications, especially catheter- 
related infections, might be expected in this immuno- 
compromised group. In the literature, only a few 
reports compare the complications of central venouc 
catheters in AIDS patients with those in patients with 
other types of immunodeficiency or with those in 
immunocompetent patients [4,6,18]. 
At present, two different types of central venous 
device are available: subcutaneously tunneled catheters 
(such as Broviac [l]  and Hickman [2] catheters) and 
totally implantable venous access devices, such as (Port- 
A-Cath). This study focuses on the last type. The daily 
use of totally implantable catheters differed slightly 
between the different investigated groups. In groups A 
and C ,  the injection procedure was performed by the 
patients themselves or their family, whereas in group B 
the doctor/nurse injected the chemotherapeutic agents. 
With respect to survival time ofpatients in the different 
groups, catheters are used for the shortest time in AIDS 
patients and longest in immunocornprtent patients. 
However, the type and incidence of coniplications of 
the totally implantable central venous catheters in the 
three groups during 1 year of catheter survival time 
were compared, as this period appears clinically relevant 
in AIDS patients with a dicorder that requires such a 
device. 
In the present retrospective study, the cumulative 
incidence of infectious catheter-related complications 
was significantly higher in immunocompetent patients 
than in both other patient groups (Figure 1).  In 
accordance with the literature, and despite the risk of 
different opportunistic infections in AIDS patients, the 
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most frequently involved microorganisms in group A 
were Staphylococcus aureus and Staphylococcus epidermidis 
13-61, In contrast to the literature, especially within the 
group of AIDS patients, infectious complications could 
not be related to degree of immunosuppression (CD4' 
lymphocyte or WBC counts) [3-51. As expected, the 
number of infectious complications was related to 
previous catheter infection and to the length of catheter 
stay in all patients. 
Only one study reported on the non-infectious 
complications in AIDS patients 141. These complica- 
tions consisted of catheter-related bleeding and catheter 
occlusion [3]. In the present study, the most important 
non-infectious complication in any patient was catheter 
occlusion. Between all groups and within each group 
occurrence of catheter occlusion could be related to 
TPN use. This was found most frequently in the group 
of immunocompetent patients, in whom the catheter 
was used for TPN nearly exclusively. Despite a high 
incidence of thrombocytopenia in AIDS patients, 
bleeding complications were observed only rarely. 
Moreover, type of complication could not be 
related to type of insertion procedure, or length of 
operation. According to the literature, catheter-related 
mortality was low in all groups (0-1%) [4,6]. 
As the present study is retrospective and the 
number of patients recruited in each group is not in 
balance, the above mentioned data should be inter- 
preted with caution. However, regarding infectious 
and non-infectious complications, the use of totally 
implantable central venous catheters appears to be safe 
and well tolerated by AIDS patients as compared to 
non-AIDS immunocompromised patients and immuno- 
competent patients. 
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